Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA approved durvalumab (Imfinzi) combined with enfortumab vedotin (Padcev) as a neoadjuvant treatment—followed by adjuvant Imfinzi—for adults with muscle-invasive bladder cancer (MIBC) who can't or won't take cisplatin. Backed by the phase 3 VOLGA trial, the regimen nearly halved the risk of disease recurrence and cut the risk of death by 42% compared to surgery alone.
The FDA has approved a new perioperative regimen for muscle-invasive bladder cancer (MIBC): durvalumab (Imfinzi) paired with enfortumab vedotin-ejfv (Padcev) as neoadjuvant therapy, followed by single-agent Imfinzi after radical cystectomy. The approval targets adults who are ineligible for or have declined cisplatin-based chemotherapy—a population with historically limited options.
The green light was driven by results from the phase 3 VOLGA trial (695 patients), which compared the combination against radical cystectomy alone. The data were compelling enough to earn an expedited review under the FDA's Project Orbis framework, with regulatory input from agencies in Australia, Brazil, Canada, Israel, Singapore, and the U.K.
By the Numbers:
Why it matters: This approval gives oncologists a powerful new tool for cisplatin-ineligible MIBC patients in a curative-intent setting, where treatment options have long been limited. It also marks AstraZeneca's third bladder cancer indication for Imfinzi in just two years.